€39.50
0.05% today
Xetra, Apr 02, 05:35 pm CET
ISIN
DE0005785604
Symbol
FRE
Sector

Fresenius Stock price

€39.50
+0.27 0.69% 1M
+5.25 15.33% 6M
+5.96 17.77% YTD
+14.89 60.50% 1Y
+6.44 19.48% 3Y
+5.40 15.84% 5Y
-15.50 28.18% 10Y
Xetra, Closing price Wed, Apr 02 2025
+0.02 0.05%
ISIN
DE0005785604
Symbol
FRE
Sector

Key metrics

Market capitalization €22.24b
Enterprise Value €34.28b
P/E (TTM) P/E ratio 47.21
EV/FCF (TTM) EV/FCF 22.03
EV/Sales (TTM) EV/Sales 1.55
P/S ratio (TTM) P/S ratio 1.00
P/B ratio (TTM) P/B ratio 1.14
Dividend yield 2.53%
Last dividend (FY24) €1.00
Revenue growth (TTM) Revenue growth -30.27%
Revenue (TTM) Revenue €22.16b
EBIT (operating result TTM) EBIT €1.82b
Free Cash Flow (TTM) Free Cash Flow €1.56b
Cash position €2.28b
EPS (TTM) EPS €0.84
P/E forward 12.93
P/S forward 0.98
EV/Sales forward 1.51
Show more

Create a Free Account to create an Fresenius alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Fresenius Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fresenius forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Fresenius forecast:

Buy
89%
Hold
11%

Financial data from Fresenius

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
22,160 22,160
30% 30%
100%
- Direct Costs 16,753 16,753
31% 31%
76%
5,407 5,407
27% 27%
24%
- Selling and Administrative Expenses 1,741 1,741
2% 2%
8%
- Research and Development Expense 641 641
17% 17%
3%
3,025 3,025
38% 38%
14%
- Depreciation and Amortization 1,204 1,204
48% 48%
5%
EBIT (Operating Income) EBIT 1,821 1,821
28% 28%
8%
Net Profit 471 471
179% 179%
2%

In millions EUR.

Don't miss a Thing! We will send you all news about Fresenius directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Stock News

AD HOC NEWS
2 days ago
Fresenius SE & Co. KGaA / DE0005785604
AD HOC NEWS
13 days ago
Das Analysehaus Jefferies hat das Kursziel für Fresenius DE0005785604 nach Jahreszahlen von 44 auf 48 Euro angehoben und die Einstufung auf "Buy" belassen.
More Fresenius News

Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Michael Sen
Employees 176,486
Founded 1912
Website www.fresenius.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today